Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
Results of medical therapy of reflux oesophagitis are disappointing, especially compared to the success obtained in peptic ulcer disease. H2-receptor antagonists, with or without the addition of mucosaprotectiva or prokinetica, produce healing only in 50% of the patients. Nowadays, even severe, resistant reflux oesophagitis can be treated successfully with the H+/K+-adenosine triphosphatase antagonist omeprazole. Experience of more than 3 years of continuous treatment with omeprazole, in doses which have been adjusted to prevent recurrences, has also demonstrated its high efficacy in the long-term management of the patients. The use of this drug emphasizes the importance of long-standing, strong acid inhibition for this condition, although careful surveillance of the safety profile of this drug remains obligatory.
Klinkenberg-Knol
E C
EC
Department of Gastroenterology, Free University Hospital, Amsterdam, The Netherlands.
Meuwissen
S G
SG
D004334:Drug Administration Schedule; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D013810:Therapeutic Equivalency
D006635:Histamine H2 Antagonists; D009853:Omeprazole